Kelly Faulk, MD

Professional Titles

• Instructor

Publications

• Faulk KE, Anderson-Mellies A, Cockburn M, Green A. Assessment of Enrollment Characteristics for Children’s Oncology Group (COG) Upfront Therapeutic Clinical Trials 2004-2015. American Society for Clinical Oncology Annual Meeting, Chicago, IL. June 2019.
• Faulk KE, Anderson-Mellies A, Cockburn M, Green AL. Assessment of enrollment characteristics for Children’s Oncology Group (COG) upfront therapeutic clinical trials 2004-2015. PLoS One. 2020; 15(4)e0230824.
• The Safety of SARS-Cov-2 Vaccines in Persons with a Known History of Pegaspargase Allergy: A Single Institution Experience. The Journal of Allergy and Clinical Immunology: In Practice, accepted with revisions.
• Faulk K, Kairalla J, Devidas M, Hibbitts E, Carroll A, Heerema N, Kubaney H, August A, Pauly M, Wechsler D, Miles R, Reid J, Druley T, Kihei C, Gore L, Raetz E, Hunger S, Loh M, Brown P, Guest E. Pegaspargase levels in infants with ALL: A report from the Children’s Oncology Group trial AALL15P1. International Society of Paediatric Oncology (SIOP), Barcelona, Spain, September 2022. Poster Presentation.
• Faulk K, Kairalla J, Devidas M, Hibbitts E, Carroll A, Heerema N, Kubaney H, August A, Pauly M, Wechsler D, Miles R, Reid J, Druley T, Kihei C, Gore L, Raetz E, Hunger S, Loh M, Brown P, Guest E. Pegaspargase levels in infants with ALL: A report from the Children’s Oncology Group trial AALL15P1. The American Society of Pediatric Hematology/Oncology (ASPHO), Pittsburgh, PA, May 2022. Poster Presentation.
• Cheung L, Aya-Bonilla C, Cruickshank M, Chiu S, Keuk V, Anderson D, Chua G-A, Singh S, Oommen J, Ferrari Em Hughes A, Ford J, Kunold E, Hesselman M, Post F, Faulk KE, Breese E, Guest E, Brown P, Loh M, Lock R, Kees U, Jafari R, Malinge S, Kotecha R. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged ALL reveals a new therapeutic strategy. Leukemia. In-press, 2022.
• Lamble A, Yeuh-Yun C, Verma A, Faulk K, Stevens A, Pommert L, Tucker S, Brookhart B, Shah NN, Brooks C, Mughal T, Cooper T. Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial. American Society of Hematology (ASH), New Orleans, LA, December 2022. Poster Presentation.
• Faulk KE, Kairalla JA, Dreyer ZE, Carroll AJ, Heerema NA, Devidas M, Carroll WL, Raetz EA, Loh ML, Hunger SP, Borowitz M, Wang C, Guest E, Brown PA. Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: report from Children’s Oncology Group study AALL0631. Pediatric Blood and Cancer 2023; 70:e30467. https://doi.org/10.1002/pbc_30467.
• Zarnegar-Lumley S, Karol SE, Pounds S, Klco JM, Luisa Sulis M, Kuo DJ, Heym KM, Ludwig K, Stevens AM, Alexander TB, Faulk KE, Sabnis HS, Tasian SK, Taub J, Place AE, Rubnitz JE. Preliminary Safety and Efficacy of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia: SELCLAX. American Society of Hematology (ASH), San Diego, CA, December 2023. Oral Presentation.
• Murphy L, Siegele B, Carstens B, Hartman L, Faulk K. A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy. Leukemia & Lymphoma 2024; 65: 843.

Practice Locations

• Children's Hospital Colorado

Specialty Information

• Pediatric Hematology / Oncology, Board Certification
• Pediatrics, Board Certification

• Cancers - Leukemia (Childhood)
• Cancers
• Cancers - Pediatric Cancer